Arcadus Therapeutics is unlocking a new class of therapeutic opportunities -- disease-driving proteins long considered inaccessible to medicine -- using a purpose-built AI platform at the convergence of structural biology and machine intelligence
Arcadus Therapeutics is unlocking a new class of therapeutic opportunities -- disease-driving proteins long considered inaccessible to medicine -- using a purpose-built AI platform at the convergence of structural biology and machine intelligence.